Page 14 - CIBEREHD-2015-eng

Organization
Scientific Production
The evolution of CIBEREHD publications can be appreciated from the following graphs in which the data from 2011 to 2015 is analysed.
Publications:
No. of affiliated publications 2015
CIBEREHD 2011 2012
Details are also given of the publications per group for the current year, as well as of interCIBER and in- traCIBER cooperation.
2013 2014 2015
581
Total publications
First quartile First Decile
EVOLUTION OF CIBEREHD PUBLICATIONS 2011-2015
700
600
500
400
300
200
100
2013 2014
MOST RELEVANT CIBEREHD PUBLICATIONS IN 2015 BY IMPACT FACTOR
Publication
Bruix J., Takayama T., mazzaferro V., Chau G.-y., yanG J., kudo m. eT al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2015;16(13):1344-1354
CharlTon m, Gane e, manns mP, Brown rs Jr, Curry mP, kwo Py, fonTana rJ, Gilroy r, TePerman l, muir aJ, mChuTChison JG, symonds wT, eT al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan;148(1):108-17
amPuero J., simon m., monToliu C., JoVer r., serra m.a., CordoBa J., romero-Gomez m. Minimal Hepatic Encephalopathy and Critical Flicker Frequency Are Associated with Survival of Patients with Cirrhosis. Gastroenterology. 2015;149(6):1483-1489.
678
408 239
615
636
626
334
326
367
372
177
160
219
200
TOTALE
1ST QUARTILE 1ST DECILE
2011 2012
2015
Impact Factor
24.690 16.716 16.716
14 I Annual report 2015 I CIBEREHD